pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,328 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1819Endpoints1412Fierce Biotech732BioSpace724BioPharma Dive532raps241onclive165fda recalls
therapy area
allOncology12552Rare Disease3274Immunology2958Cardiology2832Hematology2224Pulmonology2199Vaccines
  • Emerging biotech hubs like India could help lower global drug costs by scaling development
    The article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…
    BioSpace · 2h agoNeutral↗ source
  • Biopharma firms showcase non-amyloid Alzheimer’s strategies at CTAD 2026 conference
    Biopharma companies including Biogen, Bristol Myers Squibb and Roche gathered in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, where they presented new data on their…
    BioSpace · 2h agoPositive↗ source
← prev
page 1 of 94
next →
116
fda medwatch112
globenewswire health73
fda press59
1820
Psychiatry & CNS1223
Ophthalmology1084
Endocrinology & Metabolism785
Pain784
Nephrology767
Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concerns
Novartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
BioSpace · 2h agoNegative readoutNegative↗ source
  • BridgeBio's Morgan Paull and Christine Zhang Named BioSpace 40 Under 40, Emphasize Patient-Centric Model
    BridgeBio has seen two of its young executives, Morgan Paull and Christine Zhang, named to BioSpace’s 2026 40 Under 40 list. Their inclusion highlights the company’s rapid growth and focus on rare-…
    BioSpace · 2h agoPositive↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 5h agoLayoffsNegative↗ source
  • FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entry
    The U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…
    BioSpace · 17h agoCRLNegative↗ source
  • Medline recalls all brand beds, rails, mattresses and accessories over fire and entrapment risk
    Medline announced a recall of its entire line of Medline Brand beds, rails, mattresses and related accessories in the United States and Canada. The recall, launched on October 14, 2026, cites a po…
    fda recalls · 2d agoCRLNegative↗ source
  • PharmaLogic acquires Lantheus radiopharma CDMO and New Jersey plant to launch transatlantic manufacturing platform
    PharmaLogic announced it will purchase Lantheus' radiopharmaceutical contract development and manufacturing organization (CDMO) along with a production plant in Springfield, New Jersey. Lantheus h…
    BioSpace · 2d agoDealNeutral↗ source
  • FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer
    The U.S. Food and Drug Administration sent a complete response letter to Summit Therapeutics, declining to approve its bispecific antibody ivonescimab for patients with previously treated EGFR‑muta…
    Fierce Biotech · 2d agoRegulatoryNegative↗ source
  • Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapy
    Novo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
    BioPharma Dive · 2d agoApprovalPositive↗ source
  • Neuroscience startups attract $450M in recent funding, Oyster Therapeutics secures $60M Series A
    Venture capital activity around neuroscience has picked up again, with five neurology-focused startups collectively raising about $450 million in the past few weeks. Data from BioPharma Dive show…
    BioPharma Dive · 2d agoDealPositive↗ source
  • Windward Bio raises $225 million in IPO to fund Chinese-sourced respiratory drug program
    Windward Bio, backed by Sanofi, completed its initial public offering at the $225 million target, selling 10.3 million shares at $17 each. The proceeds will be used to advance two respiratory drug…
    Fierce Biotech · 3d agoDealPositive↗ source
  • Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitor
    Windward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
    BioPharma Dive · 3d agoDealPositive↗ source
  • Arrowhead faces challenges as Ionis's Tryngolza sales fall short, putting sHTG launch at risk
    Ionis Pharmaceuticals reported flat sales of its severe hypertriglyceridemia drug Tryngolza, generating only $9 million and cutting its annual revenue outlook to $50 million. The weak performance…
    BioSpace · 2d agoEarningsNegative↗ source
  • HHS commits up to $25M for ibogaine and other psychotropic drugs on Veteran's Day
    HHS announced an investment of up to $25 million for ibogaine and other rapid acting psychotropic medicines aimed at serious mental illnesses such as PTSD, unveiled on Veteran's Day. Up to $4.9 mi…
    BioSpace · 2d agoDealPositive↗ source
  • Regeneron's POTS antibody shows heart-rate reduction in Phase 2, paving way for Phase 3 trial
    Regeneron reported results from its Phase 2 Pinnacle trial of a monoclonal antibody targeting postural orthostatic tachycardia syndrome (POTS), a disorder with no approved therapies. The trial enr…
    BioSpace · 2d agoPositive readoutPositive↗ source
  • Gate Bioscience eyes clinic trials with molecular gate drugs, backed by expanded $870M Lilly partnership
    Gate Bioscience is developing small-molecule drugs that block the Sec61 channel, preventing disease-causing proteins from entering cells and leading to their degradation. The company's first discl…
    Fierce Biotech · 2d agoDealPositive↗ source
  • Charles River acquires two Frontage bioanalysis labs in Pennsylvania for $470 million
    Charles River Laboratories announced it has purchased two laboratory sites from Tigermed’s Frontage in Exton, Pennsylvania, paying $470 million upfront. The labs together span about 150,000 square…
    Fierce Biotech · 2d agoDealPositive↗ source
  • Rezolute’s phase 3 trial of ersodetug meets primary endpoint in tumor hyperinsulinism
    Rezolute reported that its phase 3 Uplift study of ersodetug in tumor hyperinsulinism achieved its primary endpoint. The trial required at least nine of 16 patients to show a 50% or greater reduct…
    Fierce Biotech · 2d agoPositive readoutPositive↗ source
  • Virtuoso Surgical receives FDA De Novo clearance for robotic bladder lesion removal system
    Virtuoso Surgical's Virtuoso Endoscopy System received FDA De Novo authorization, marking the first device in a new classification for electromechanical surgical technologies that use robotic instr…
    Fierce Biotech · 3d agoApprovalPositive↗ source
  • Cellectis to cut 70% of staff as it shifts focus from allogeneic CAR-T to in vivo gene editing
    Cellectis announced that roughly seven out of ten employees will be let go as the Paris‑based biotech restructures its operations. The company previously abandoned its two clinical‑stage allogenei…
    Fierce Biotech · 3d agoLayoffsNegative↗ source
  • Windward Bio raises $175M in IPO, boosting 2026 biotech debut count to 35
    Windward Bio completed an initial public offering that raised about $175 million, selling roughly 10.3 million shares at $17 each on the Nasdaq. The proceeds are earmarked to advance its lead antib…
    BioSpace · 2d agoDealPositive↗ source
  • ObesityWeek 2026 to showcase amylin pathway and emerging weight-loss mechanisms
    ObesityWeek 2026 starts Saturday in Washington, DC, gathering weight-loss experts and biopharma companies with metabolic assets. The meeting will highlight the amylin pathway and other emerging me…
    BioSpace · 2d agoNeutral↗ source
  • bioQuad recalls OsteoDenx capsules after discovering undeclared milk, warning allergic consumers
    bioQuad Life Sciences announced a recall of two lots of its OsteoDenx dietary supplement capsules because they contain undeclared milk. The presence of milk, specifically lactoferrin derived from…
    fda recalls · 2d agoCRLNegative↗ source
  • Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trial
    Regeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.
    Fierce Biotech · 3d agoNeutral↗ source